Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib + belzutifan in multiple advanced solid tumors
NL-OMON54355Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, lenvatinib and belzutifan in hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and 3 more, sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicity, Adverse events and 2 more. Started Aug 2021; status: recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)biliary cancerEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NL-OMON54355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54355.